Novel Prostate Cancer Cell Lines to Address Prostate Cancer Disparity in Black Men

这项工作是基于这样的假设，即为了充分利用基于细胞系的药物的益处， 筛选，代表性的细胞系小组概括了不同类型的前列腺癌（PCa） 祖先的差异是必要的。前列腺癌是导致癌症的主要原因 全世界男性的死亡率。目前在患者诊断和治疗方面的进展已经导致了 PCa发病率和死亡率下降。然而，非洲人的情况并非如此。 来自非洲和加勒比地区的非洲人后裔（MAA），其中PCa发病率和死亡率均为 在上升。PCa细胞系用于了解PCa的生物学，并促进PCa的研究。 PCa治疗诊断学的发展。然而，超过97%的PCa细胞系， 研究人员可以从欧洲血统的男性（MEA）。仍然有有限的 当与MEA相比时，来自MAA的PCa材料的代表性，并且几乎没有细胞 从MAA衍生的模型。这使得很难评估潜在的 在MAA与MEA的治疗，有助于在健康差距的问题。为了解决这个 问题，该项目将首先开发和表征细胞系， MAA中与PCa相关的普遍分子异常（目的1）。二是会 比较筛选化疗药物和牙买加天然先导分子的新颖性 MAA PCa细胞系标准地采用衍生自MEA的PCa细胞系（目标2）。

This work is based on the hypothesis that to fully exploit the benefit of cell line-based drug screening, a representative cell line panel recapitulating the varied types of prostate cancer (PCa) and the contribution of differences in ancestry is necessary. PCa is the leading cause of cancer mortality in men worldwide. Current advances in patient diagnoses and therapy have led to a decline in PCa incidence and mortality rates. However, this is not the case for men of African ancestry (MAA) from Africa and the Caribbean where both PCa incidence and mortality rates are on the rise. PCa cell lines are used to understand the biology of PCa and to advance the development of PCa theranostics. However, more than 97% of the PCa cell lines that are readily available to researchers are from men of European ancestry (MEA). There continues to be limited representation of PCa materials from MAA when compared to MEA, and there are almost no cell models available derived from MAA. This makes it difficult to assess the efficacy of potential treatments in MAA versus MEA, contributing to a problem in health disparities. To address this problem, this project will first develop and characterize cell lines that recapitulate the most prevalent molecular abnormalities associated with PCa in MAA (Aim 1). Second, it will comparatively screen chemotherapy drugs and Jamaican natural lead molecules on the novel MAA PCa cell lines to standardly employed PCa cell lines derived from MEA (Aim 2).